By Dave Sebastian

 

Merck & Co. Inc. said the European Commission has approved its Keytruda drug in combination with chemotherapy for the treatment of certain patients with esophageal cancer.

The approval lets the company market the Keytruda combination in all 27 European Union member states, as well as Iceland, Lichtenstein, Norway and Northern Ireland, Merck said Tuesday.

Merck said the approval is based on a Phase 3 trial in which a Keytruda combination demonstrated improvements in overall survival and progression-free survival.

The company said it is continuing to study Keytruda in multiple settings and stages of gastrointestinal cancer, including studies in esophageal, gastric, hepatobiliary, pancreatic, colorectal and anal cancers.

 

Write to Dave Sebastian at dave.sebastian@wsj.com

 

(END) Dow Jones Newswires

June 29, 2021 07:14 ET (11:14 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Merck Charts.